Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
32.13
+0.43 (1.36%)
At close: May 12, 2025, 4:00 PM
32.45
+0.32 (1.00%)
After-hours: May 12, 2025, 7:38 PM EDT
Cytokinetics Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Cytokinetics stock have an average target of 77.33, with a low estimate of 41 and a high estimate of 120. The average target predicts an increase of 140.68% from the current stock price of 32.13.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 6 | 6 | 6 |
| Buy | 8 | 8 | 9 | 9 | 10 | 10 |
| Hold | 4 | 3 | 2 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 17 | 17 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $55 → $53 | Buy | Maintains | $55 → $53 | +64.95% | May 8, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $82 → $80 | Buy | Maintains | $82 → $80 | +148.99% | May 7, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $86 → $80 | Strong Buy | Maintains | $86 → $80 | +148.99% | May 7, 2025 |
| UBS | UBS | Hold Maintains $47 → $41 | Hold | Maintains | $47 → $41 | +27.61% | May 2, 2025 |
| Needham | Needham | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +124.09% | May 2, 2025 |
Financial Forecast
Revenue This Year
28.79M
from 18.47M
Increased by 55.84%
Revenue Next Year
215.05M
from 28.79M
Increased by 646.96%
EPS This Year
-5.84
from -5.26
EPS Next Year
-4.78
from -5.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 67.3M | 415.8M | 827.5M | ||
| Avg | 28.8M | 215.1M | 501.4M | ||
| Low | 6.4M | 101.2M | 340.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 264.3% | 1,344.3% | 284.8% | ||
| Avg | 55.8% | 647.0% | 133.2% | ||
| Low | -65.5% | 251.6% | 58.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -5.15 | -3.38 | -0.72 | ||
| Avg | -5.84 | -4.78 | -2.50 | ||
| Low | -6.56 | -6.37 | -4.85 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.